Amicus Therapeutics, Inc. (FOLD) Q3 2017 Earnings Results

Amicus Therapeutics Beats on EPS, Stock Down 7.3%

Amicus Therapeutics reported a significant EPS beat, which indicates better-than-expected profitability. However, the stock fell by 7.3% in reaction to the lack of revenue figures and future guidance. Investors may be concerned about the absence of clarity on revenue growth and overall business direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.41	N/A	+246.18%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management expressed satisfaction with the EPS results but did not provide any guidance for future performance. The focus remains on ongoing projects and developments.

Management highlighted the strong performance in EPS despite the lack of revenue guidance.

There was no specific outlook provided for future quarters.

Amicus Therapeutics Beats on EPS, Stock Down 7.3%

Key numbers

Management commentary

Amicus Therapeutics, Inc.

More earnings this week

Amicus Therapeutics Beats on EPS, Stock Down 7.3%

Key numbers

Management commentary